Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.59 | N/A |
Market Cap | $4.81M | N/A |
Shares Outstanding | 8.16M | -29.05% |
Employees | 0 | N/A |
Shareholder Equity | 33.15M | -61.06% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.16 | N/A |
P/S Ratio | 327.44 | N/A |
P/B Ratio | 0.15 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.6407 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $14.70K | N/A |
Earnings | -$21.24M | N/A |
EPS | -3.60 | N/A |
Earnings Yield | -6.10 | N/A |
Operating Margin | -1.45K | N/A |
Net income margin | -1.44K | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $43.00M | N/A |
Total Debt | $533.58K | N/A |
Cash on Hand | $18.25M | N/A |
Debt to Equity | 0.2973 | 101.52% |
Cash to Debt | $34.20 | -29.32% |
Current Ratio | $4.87 | -60.94% |